VIGENERON
ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV gene therapy vector platform, allows superior transduction efficiency and intravitreal, less invasive treatment administration. The second, REVeRT vector platform, targets diseases caused by mutations in large genes. Privately-owned ViGeneron was founded in 2017 by a seasoned team with in-depth experience in AAV vector technology and clinical ophthalmic gene therapy programs and is located in Munich, Germany.
VIGENERON
Industry:
Biotechnology Health Care Therapeutics
Founded:
2017-01-01
Address:
Starnberg, Bayern, Germany
Country:
Germany
Website Url:
http://www.vigeneron.com
Total Employee:
1+
Status:
Active
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins Sitelinks Search Box Euro
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Celergen USA
Celergen USA is a health care cell therapy company.
Exegenesis Bio
Exegenesis Bio is a Gene therapy start-up.
Current Employees Featured
Founder
Investors List
WuXi AppTec
WuXi AppTec investment in Series A - ViGeneron
Sequoia Capital China
Sequoia Capital China investment in Series A - ViGeneron
Official Site Inspections
http://www.vigeneron.com
- Host name: dd42334.kasserver.com
- IP address: 85.13.157.250
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
